PCDVD數位科技討論區
PCDVD數位科技討論區   註冊 常見問題 標記討論區為已讀

回到   PCDVD數位科技討論區 > 其他群組 > 七嘴八舌異言堂
帳戶
密碼
 

  回應
 
主題工具
BJ4
*停權中*
 

加入日期: Nov 2017
文章: 44
引用:
作者LDSKING
然後你房貸工期款搞懂沒?穿軍服開軍車可以去買永和豆漿你搞懂沒?

沒有就去旁邊玩沙當什麼閱障救援王

穿軍服開軍車你被我甩八掌還可以精神勝利以為贏了到處說嘴

房貸挖上來我跟你戰阿 不敢
反正你也當歸兒子很久了

腦水 算術障礙你搞懂了沒

沒有就去旁邊玩沙當什麼閱障救援王
     
      

此文章於 2021-05-09 06:15 PM 被 BJ4 編輯.
舊 2021-05-09, 06:12 PM #91
回應時引用此文章
BJ4離線中  
BJ4
*停權中*
 

加入日期: Nov 2017
文章: 44
引用:
作者中國戰螂
我不是講過了嗎?
我不是用這篇文章否認他篇文章(報紙...),

沒基本知識, 或是不願意推論的, 認為報紙說的就是一切的, 就請去看報紙就好
我不想多費唇舌, 我又沒跟你們收錢

我看你也沒基本常識阿
也不願意推論
認為blog說的就是一切

套用你說過的話

我不是對你有成見, 因為你所謂的根據就是blog, 要不然就是沒根據
 
舊 2021-05-09, 06:14 PM #92
回應時引用此文章
BJ4離線中  
中國戰螂
*停權中*
 

加入日期: Feb 2021
文章: 0
引用:
作者BJ4
我看你也沒基本常識阿
也不願意推論
認為blog說的就是一切

套用你說過的話

我不是對你有成見, 因為你所謂的根據就是blog, 要不然就是沒根據


我沒說誰的言論沒根據啊???

貼一則你們不愛看的


巴西東南部一個擁有約4.5萬居民的小鎮塞拉納(Serrana)數月以來一直在進行一項實驗,讓所有18歲以上居民接種大陸科興疫苗。巴西目前新冠肺炎疫情仍然相當嚴重,但據稱這個小鎮的生活已經開始恢復正常。

據《華爾街日報》報導,塞拉納鎮原本是確診相當嚴重的城鎮,但衛生廳的布坦坦研究所為了要研究疫苗效果,自2月起啟動「S計劃」,為當地所有18歲以上民眾接種中國科興疫苗;鎮上居民相當期待,紛紛主動排隊參加計劃。4月時官方宣布鎮上已有27150人接種兩劑疫苗,達到目標接種人群的約97.7%。

目前鎮上單月確診數已大幅減少,在醫院排隊等待使用呼吸機的病患冗長隊伍,也已漸漸消失。有研究人員保守表示,現在就下結論為時過早,但早期結果還是相當令人振奮。報導指出,現在鎮上的孩子可以自由的在廣場奔跑,親朋好友在路上遇到也可以自在的聊天,在戶外曬太陽也成為理所當然的事情。


巴西小鎮上萬人 全部接種大陸「科興疫苗」結果出爐
舊 2021-05-09, 07:22 PM #93
回應時引用此文章
中國戰螂離線中  
silent
Major Member
 

加入日期: Dec 2012
文章: 182
引用:
作者中國戰螂
我沒說誰的言論沒根據啊???

貼一則你們不愛看的


巴西東南部一個擁有約4.5萬居民的小鎮塞拉納(Serrana)數月以來一直在進行一項實驗,讓所有18歲以上居民接種大陸科興疫苗。巴西目前新冠肺炎疫情仍然相當嚴重,但據稱這個小鎮的生活已經開始恢復正常。

據《華爾街日報》報導,塞拉納鎮原本是確診相當嚴重的城鎮,但衛生廳的布坦坦研究所為了要研究疫苗效果,自2月起啟動「S計劃」,為當地所有18歲以上民眾接種中國科興疫苗;鎮上居民相當期待,紛紛主動排隊參加計劃。4月時官方宣布鎮上已有27150人接種兩劑疫苗,達到目標接種人群的約97.7%。

目前鎮上單月確診數已大幅減少,在醫院排隊等待使用呼吸機的病患冗長隊伍,也已漸漸消失。有研究人員保守表示,現在就下結論為時過早,但早期結果還是相當令人振奮。報導指出,現在鎮上的孩子可以自由的在廣場奔跑,親朋好友在路上遇到也可以自在的聊...


https://www.pcdvd.com.tw/showpost.p...22&postcount=70
我前面的貼文裡早已經說了,中國疫苗的有效力從約50%到超過90%都有數據,你這個不就是裡面巴西的例子?

況且之前你是在說mRNA疫苗對於變異病毒效果不如滅活病毒吧?副作用也比較大?怎麼不提了?

哈佛醫學5/7的文章對於變異病毒目前兩種最主要的mRNA疫苗效用的評論:
https://www.health.harvard.edu/coro...vid-19-vaccines

沒空細翻,就是對變異病毒都有蠻高的效用,重點是最後指出,目前兩種mRNA疫苗都是極其有效的,就算對變異略有降低,還是有相當程度的效力。

引用:
….
Will the COVID-19 mRNA vaccines work against the new coronavirus variants?

Mutations have led to several new, concerning coronavirus variants, including the B.1.1.7 variant, which was first detected in the United Kingdom; the B.1.351 variant, which originated in South Africa; and the P.1 variant, which originated in Brazil. Emerging evidence suggests that the current mRNA vaccines are effective against at least some of these variants. Two peer-reviewed and published studies have found the Pfizer/BioNTech vaccine to be extremely effective against the B.1.1.7 and the B.1.351 variants. The first study, published in NEJM, looked at data from more than 200,000 people from the country of Qatar between early February and late March 2021. During that time, the B.1.1.7 and B.1.351 variants were responsible for nearly all COVID cases in that country. The researchers found that in people who were fully vaccinated, the Pfizer vaccine was 97.4% effective at preventing severe, critical, or fatal disease caused by the B.1.1.7 or B.1.351 variants.

The second study, published in The Lancet, looked at more than 200,000 COVID infections in Israel from late January to early April 2021, when the B.1.1.7 variant accounted for more than 90% of infections. The researchers found that in fully vaccinated people, the Pfizer vaccine was nearly 97% or more effective at preventing symptomatic COVID-19, COVID-related hospitalization, severe or critical COVID-19, or COVID-related death.

In the lab, the Moderna vaccine has also performed well against the B.1.1.7 variant. However, it was less effective against the B.1.351 variant; in a laboratory study, the vaccine resulted in fewer neutralizing antibodies being produced against the B.1.351 variant, compared to the unmutated virus and the B.1.1.7 variant. More study is needed to see if the laboratory results hold up in real-world conditions.

Neither company has released data regarding the P.1 variant, which shares some of the same mutations as the B.1.351 variant.

Both Moderna and Pfizer/BioNTech have announced plans to study variant-specific vaccine boosters, designed to specifically target the B.1.351 variant. In addition, both companies are testing whether a third dose of their existing, FDA-authorized vaccines provides additional protection against variants of concern.

Early laboratory evidence suggests that antibodies created in response to both the Pfizer/BioNTech and Moderna mRNA vaccines are effective against another new variant known as the New York variant, or B.1.526.

It's important to remember that both the Pfizer/BioNTech and Moderna vaccines are extremely effective — 95% and 94.1%, respectively. Even with a drop in effectiveness, they will still provide protection.

….

此文章於 2021-05-10 01:01 AM 被 silent 編輯.
舊 2021-05-10, 12:57 AM #94
回應時引用此文章
silent離線中  
中國戰螂
*停權中*
 

加入日期: Feb 2021
文章: 0
引用:
作者silent
...............

況且之前你是在說mRNA疫苗對於變異病毒效果不如滅活病毒吧?副作用也比較大?怎麼不提了?

哈佛醫學5/7的文章對於變異病毒目前兩種最主要的mRNA疫苗效用的評論:
https://www.health.harvard.edu/coro...vid-19-vaccines

沒空細翻,就是對變異病毒都有蠻高的效用,重點是最後指出,目前兩種mRNA疫苗都是極其有效的,就算對變異略有降低,還是有相當程度的效力。


mRNA在目前, 效果很好啊???

cdx 講的是:
理論上mRNA疫苗比較精準打擊原先病毒
但是對變異的病毒防護力可能會比滅活疫苗差

我看起來, 這段話與你說的 "mRNA疫苗對於變異病毒效果不如滅活病毒" 意思不同

因為mRNA是針對spike protein 做疫苗, spike protein又是covid-19變異最快的,
舊 2021-05-10, 05:23 AM #95
回應時引用此文章
中國戰螂離線中  
silent
Major Member
 

加入日期: Dec 2012
文章: 182
引用:
作者中國戰螂
mRNA在目前, 效果很好啊???

cdx 講的是:
理論上mRNA疫苗比較精準打擊原先病毒
但是對變異的病毒防護力可能會比滅活疫苗差

我看起來, 這段話與你說的 "mRNA疫苗對於變異病毒效果不如滅活病毒" 意思不同

因為mRNA是針對spike protein 做疫苗, spike protein又是covid-19變異最快的,


引用:
但是對變異的病毒防護力可能會比滅活疫苗差

引用:
mRNA疫苗對於變異病毒效果不如滅活病毒

whatever
舊 2021-05-10, 05:50 AM #96
回應時引用此文章
silent離線中  
中國戰螂
*停權中*
 

加入日期: Feb 2021
文章: 0
引用:
作者silent
whatever


"目前" mRNA 疫苗效果, 還勝過滅活疫苗

你再繼續講:
我說過 "mRNA疫苗對於變異病毒效果不如滅活病毒"
那就是你人格問題了

我在哪裡說過呢?
舊 2021-05-10, 06:23 AM #97
回應時引用此文章
中國戰螂離線中  
silent
Major Member
 

加入日期: Dec 2012
文章: 182
who cares
舊 2021-05-10, 06:33 AM #98
回應時引用此文章
silent離線中  
厝漢
Major Member
 
厝漢的大頭照
 

加入日期: Jun 2009
您的住址: 厝漢當然是龜在厝裡
文章: 223
何時要像 危機總動員 用炸彈來解決問題呢!?



我看阿三 是沒救了。那個環境 根本就是 病毒最好的溫床。
__________________
這是一個你努力,都不一定會成功的世界~~~~~~~~~

此文章於 2021-05-10 06:49 AM 被 厝漢 編輯.
舊 2021-05-10, 06:35 AM #99
回應時引用此文章
厝漢離線中  
silent
Major Member
 

加入日期: Dec 2012
文章: 182
這篇”新英格蘭醫學雜誌”刊登的文章,整理目前卡達(Qatar)使用輝瑞疫苗(Pfizer–BioNTech)碰上COVID 變異病毒的效用,應該就是前面哈佛醫學期刊引用的文章。

https://www.nejm.org/doi/full/10.1056/NEJMc2104974

卡達從去年12/21開始大規模施打Pfizer疫苗,到3/31為止共有385,853人至少打過一劑疫苗,其中265,410人打完兩劑.

引用:
Viral genome sequencing conducted from February 23 through March 18 indicated that 50.0% of cases of Covid-19 in Qatar were caused by B.1.351 and 44.5% were caused by B.1.1.7. Nearly all cases in which virus was sequenced after March 7 were caused by either B.1.351 or B.1.1.7.

在2/23之後的COVID感染病例經基因定序後發現幾乎95%以上都是變異株病毒,B.1.351 or B.1.1.7都包括.

引用:
The estimated effectiveness of the vaccine against any documented infection with the B.1.1.7 variant was 89.5% (95% confidence interval [CI], 85.9 to 92.3) at 14 or more days after the second dose (Table 1 and Table S2). The effectiveness against any documented infection with the B.1.351 variant was 75.0% (95% CI, 70.5 to 78.9). Vaccine effectiveness against severe, critical, or fatal disease due to infection with any SARS-CoV-2 (with the B.1.1.7 and B.1.351 variants being predominant within Qatar) was very high, at 97.4% (95% CI, 92.2 to 99.5).

依據所有紀錄估計對B.1.1.7的免疫力為85.9%,對B.1.351為75%,而總體對防止感染發展變為重症的防禦率高達97.4%.

也就是說雖然對預防變異病毒感染的效力下降,但總體結果而言,即使感染後仍有高達97%以上的效力防止變為重症,
舊 2021-05-10, 07:52 AM #100
回應時引用此文章
silent離線中  


    回應


POPIN
主題工具

發表文章規則
不可以發起新主題
不可以回應主題
不可以上傳附加檔案
不可以編輯您的文章

vB 代碼打開
[IMG]代碼打開
HTML代碼關閉



所有的時間均為GMT +8。 現在的時間是01:56 PM.


vBulletin Version 3.0.1
powered_by_vbulletin 2024。